血管内皮细胞中的凝血物质:理论研究新进展
|
摘要
背景:血管内皮细胞在凝血过程中能够分泌众多凝血物质参与凝血级联反应或收缩血管促进凝血进程。目的:综述血管内皮细胞分泌的不同凝血物质的作用机制,为凝血功能材料的筛选提供理论依据。方法:应用计算机检索中国知网、Pub Med数据库1988至2016年收录的与血管内皮细胞凝血物质相关的文献。英文检索词为"Vascular endothelial cells,endothelin,AngⅡ,TXA2,tissue factor,Collagen,fibronectin,von wilbrand factor,thrombospondin,platelet activating factor,plasminogen activator inhibitor,proaccelerin,antihemophlic factor",中文检索词为"血管内皮细胞,组织因子,胶原,纤维连接蛋白,血小板激活因子,纤溶酶原激活物抑制物,凝血因子Ⅴ、Ⅷ,内皮素,血管紧张素Ⅱ,血栓素",最终纳入文献38篇进行综述。结果与结论:血管损伤时血管内皮细胞产生的众多凝血因子在凝血、炎症反应以及血栓形成过程中发挥着重要的作用。凝血过程中,血管内皮细胞分泌众多促凝因子和凝血因子Ⅴ和Ⅷ直接参与凝血级联瀑布反应,促进血栓形成;同时血管内皮细胞分泌的收缩血管因子使血管腔狭小,辅助凝血过程,间接促进血栓形成。
BACKGROUND: Vascular endothelial cells participate in the coagulation cascade reaction or contraction of blood vessels by secreting abundant coagulating substances that promote coagulation. OBJECTIVE: To overview the effects of different coagulating substances secreted by vascular endothelial cells, and provide theoretical basis for the screening of coagulant biomaterials.METHODS: A computer-based research in CNKI and Pub Med databases was performed for relevant literatures addressing vascular endothelial cells and its secreting coagulating substances published from 1988 to 2016 usingthe keywords of "vascular endothelial cells, endothelin, Ang II, TXA2, tissue factor, collagen, fibronectin, von wilbrand factor, thrombospondin, platelet activating factor, plasminogen activator inhibitor, proaccelerin, antihemophlic factor" in English and Chinese, respectively. Finally 36 articles were enrolled for result analysis. RESULTS AND CONCLUSION: Vascular endothelial cells can secrete numerous coagulation factors that play important roles in the process of coagulation, inflammation reaction and thrombosis following vascular injury. Among them, coagulation factor V and VIII are directly involved in the coagulation cascade reaction and promote thrombosis. In the meanwhile, the vasoconstrictors narrow the lumen, thereby assisting coagulation and promoting thrombosis indirectly.
BACKGROUND: Vascular endothelial cells participate in the coagulation cascade reaction or contraction of blood vessels by secreting abundant coagulating substances that promote coagulation. OBJECTIVE: To overview the effects of different coagulating substances secreted by vascular endothelial cells, and provide theoretical basis for the screening of coagulant biomaterials.METHODS: A computer-based research in CNKI and Pub Med databases was performed for relevant literatures addressing vascular endothelial cells and its secreting coagulating substances published from 1988 to 2016 usingthe keywords of "vascular endothelial cells, endothelin, Ang II, TXA2, tissue factor, collagen, fibronectin, von wilbrand factor, thrombospondin, platelet activating factor, plasminogen activator inhibitor, proaccelerin, antihemophlic factor" in English and Chinese, respectively. Finally 36 articles were enrolled for result analysis. RESULTS AND CONCLUSION: Vascular endothelial cells can secrete numerous coagulation factors that play important roles in the process of coagulation, inflammation reaction and thrombosis following vascular injury. Among them, coagulation factor V and VIII are directly involved in the coagulation cascade reaction and promote thrombosis. In the meanwhile, the vasoconstrictors narrow the lumen, thereby assisting coagulation and promoting thrombosis indirectly.
引文
[1]Jin HM.A study on content and distribution of plasma and tissue fibronectin in rats using ELISA and immunofluorescence.J Tongji Med Univ.1990;10(4):193-200.
[2]陈临溪.血管内皮细胞药理与临床[M].北京:人民军医出版社,2012.
[3]张靖.组织因子(TF)与胃癌发生发展的关系[D].西安:第四军医大学,2005.
[4]Giesen PL,Nemerson Y.Tissue factor on the loose.Semin Thromb Hemost.2000;26(4):379-384.
[5]Yang J,Lee GF,Riederer MA,et al.Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa.Thromb Haemost.2002;87(3):450-458.
[6]Ero?lu A,Ceylan GG,Ozturk,et al.The efficacy of tissue factor-603A/G and+5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.Exp Oncol.2016;38(3):187-190.
[7]Wilson GJ,Courtman DW,Klement P,et al.Acellular matrix:a biomaterials approach for coronary artery bypass and heart valve replacement.Ann Thorac Surg.1995;60(2 Suppl):S353-358.
[8]李国英.胶原的类型及其结构特征[J].中国皮革,2002,31(17):20-21.
[9]Olorundare OE,Peyruchaud O,Albrecht RM,et al.Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.Blood.2001;98(1):117-124.
[10]刘郁倩,但年华,但卫华.胶原止血性能的研究进展[J].西部皮革,2013,35(12):21-25.
[11]Lode A,Meyer M,Brüggemeier S,et al.Additive manufacturing of collagen scaffolds by three-dimensional plotting of highly viscous dispersions.Biofabrication.2016;8(1):015015.
[12]韩倩倩,王春仁,戴建武.功能胶原蛋白生物材料与组织再生[J].中国医疗器械信息,2012,18(2):1-6.
[13]李庆生.纤维连接蛋白在血栓形成中的作用及其临床意义[D].合肥:安徽医科大学,2005.
[14]Llopis-Hernández V,Cantini M,González-García C,et al.Material-driven fibronectin assembly for high-efficiency presentation of growth factors.Sci Adv.20166;2(8):e1600188.
[15]胡凤蓉,高帆,杨庆,等.因子V Leiden突变在布加综合征与门静脉血栓形成中的意义[J].临床肝胆病杂志,2014,30(1):86-89.
[16]仲立军,姜玮,王凤山,等.人凝血因子Ⅷ的研究进展[J].食品与药品,2014,16(3):212-214.
[17]Kim TH,Baek SH,Lim JO,et al.Genetic variation in the coagulation factor V gene and risk of femoral head osteonecrosis.Mol Med Rep.2015;12(3):4434-4440.
[18]Arnaez J,Arca G,Martín-Ancel A,et al.Coagulation factor VG1691A,factor II G20210A and methylenetetrahydrofolate reductase C677T gene mutations do not play a major role in symptomatic neonatal arterial ischaemic stroke.Br JHaematol.2016 Sep 13.[Epub ahead of print]
[19]王保岚,张曼华.血管性假血友病因子、血栓调节蛋白与糖尿病肾病的关系研究[J].医学综述,2008,14(5):730-733.
[20]韩纪举,魏然,李震,等.慢性肝炎患者血浆v WF及其前肽与纤溶系统测定的临床意义[J].医学争鸣,2005,26(14):1289-1292.
[21]奚晓东,阮长耿,李佩霞,等.抗von Willebrand因子单克隆抗体的研究和应用[J].苏州大学学报:医学版,1988,8(3):249-250.
[22]Stockschlaeder M,Schneppenheim R,Budde U.Update on von Willebrand factor multimers:focus on high-molecular-weight multimers and their role in hemostasis.Blood Coagul Fibrinolysis.2014;25(3):206-216.
[23]Nossent JC,Raymond WD,Eilertsen G?.Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.Lupus Sci Med.2016;3(1):e000162.
[24]Lawler J.The functions of thrombospondin-1 and-2.Curr Opin Cell Biol.2000;12(5):634-640.
[25]Krishna SM,Golledge J.The role of thrombospondin-1 in cardiovascular health and pathology.Int J Cardiol.2013;168(2):692-706.
[26]Lin CY,Lin CY,Chang IW,et al.Low thrombospondin 2expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.Am J Transl Res.2015;7(11):2423-2432.
[27]杨建东.血小板激活因子[J].中华危重病急救医学,1996,8(8):502-505.
[28]吴勇杰,周尔凤.血小板激活因子与血小板的相互作用[J].中国药理学通报,1987,3(3):176-179.
[29]Hammond JW,Lu SM,Gelbard HA.Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC,Elevated Intracel ular Calcium,and Modulation of Synapsin 1 Dynamics and Phosphorylation.Front Cell Neurosci.2016;9:505.
[30]王文革,王俭勤.纤溶酶原激活物抑制物1和器官纤维化[J].医学综述,2010,16(9):1308-1310.
[31]Eddy AA.Serine proteases,inhibitors and receptors in renal fibrosis.Thromb Haemost.2009;101(4):656-664.
[32]赵晶,戚基萍,王德生.纤溶酶原激活物抑制物和脑血栓[J].黑龙江医学,2002,26(2):95-96.
[33]Tofler GH,Massaro J,O'Donnell CJ,et al.Plasminogen activator inhibitor and the risk of cardiovascular disease:The Framingham Heart Study.Thromb Res.2016;140:30-35.
[34]刘向辉,陈松娥,刘桂华.内皮素与心血管疾病的研究进展[J].天津体育学院学报,2005,20(2):49-52.
[35]潘雪峰,董华进,宫泽辉.内皮素与心血管功能研究的最新进展[J].国际药学研究杂志,2007,34(1):12-16.
[36]甘金莲,樊有赋,陈晔,等.内皮素的特性与生理病理作用[J].生物学教学,2009,34(4):2-4.
[37]陈欢.高剂量Ang II对血管内皮细胞ACE、ACE2表达的影响及其分子机制[D].广州:南方医科大学,2013.
[38]龚勇珍.血栓素A_2受体研究进展[J].临床与病理杂志,2004,24(1):28-31.
[2]陈临溪.血管内皮细胞药理与临床[M].北京:人民军医出版社,2012.
[3]张靖.组织因子(TF)与胃癌发生发展的关系[D].西安:第四军医大学,2005.
[4]Giesen PL,Nemerson Y.Tissue factor on the loose.Semin Thromb Hemost.2000;26(4):379-384.
[5]Yang J,Lee GF,Riederer MA,et al.Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa.Thromb Haemost.2002;87(3):450-458.
[6]Ero?lu A,Ceylan GG,Ozturk,et al.The efficacy of tissue factor-603A/G and+5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.Exp Oncol.2016;38(3):187-190.
[7]Wilson GJ,Courtman DW,Klement P,et al.Acellular matrix:a biomaterials approach for coronary artery bypass and heart valve replacement.Ann Thorac Surg.1995;60(2 Suppl):S353-358.
[8]李国英.胶原的类型及其结构特征[J].中国皮革,2002,31(17):20-21.
[9]Olorundare OE,Peyruchaud O,Albrecht RM,et al.Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.Blood.2001;98(1):117-124.
[10]刘郁倩,但年华,但卫华.胶原止血性能的研究进展[J].西部皮革,2013,35(12):21-25.
[11]Lode A,Meyer M,Brüggemeier S,et al.Additive manufacturing of collagen scaffolds by three-dimensional plotting of highly viscous dispersions.Biofabrication.2016;8(1):015015.
[12]韩倩倩,王春仁,戴建武.功能胶原蛋白生物材料与组织再生[J].中国医疗器械信息,2012,18(2):1-6.
[13]李庆生.纤维连接蛋白在血栓形成中的作用及其临床意义[D].合肥:安徽医科大学,2005.
[14]Llopis-Hernández V,Cantini M,González-García C,et al.Material-driven fibronectin assembly for high-efficiency presentation of growth factors.Sci Adv.20166;2(8):e1600188.
[15]胡凤蓉,高帆,杨庆,等.因子V Leiden突变在布加综合征与门静脉血栓形成中的意义[J].临床肝胆病杂志,2014,30(1):86-89.
[16]仲立军,姜玮,王凤山,等.人凝血因子Ⅷ的研究进展[J].食品与药品,2014,16(3):212-214.
[17]Kim TH,Baek SH,Lim JO,et al.Genetic variation in the coagulation factor V gene and risk of femoral head osteonecrosis.Mol Med Rep.2015;12(3):4434-4440.
[18]Arnaez J,Arca G,Martín-Ancel A,et al.Coagulation factor VG1691A,factor II G20210A and methylenetetrahydrofolate reductase C677T gene mutations do not play a major role in symptomatic neonatal arterial ischaemic stroke.Br JHaematol.2016 Sep 13.[Epub ahead of print]
[19]王保岚,张曼华.血管性假血友病因子、血栓调节蛋白与糖尿病肾病的关系研究[J].医学综述,2008,14(5):730-733.
[20]韩纪举,魏然,李震,等.慢性肝炎患者血浆v WF及其前肽与纤溶系统测定的临床意义[J].医学争鸣,2005,26(14):1289-1292.
[21]奚晓东,阮长耿,李佩霞,等.抗von Willebrand因子单克隆抗体的研究和应用[J].苏州大学学报:医学版,1988,8(3):249-250.
[22]Stockschlaeder M,Schneppenheim R,Budde U.Update on von Willebrand factor multimers:focus on high-molecular-weight multimers and their role in hemostasis.Blood Coagul Fibrinolysis.2014;25(3):206-216.
[23]Nossent JC,Raymond WD,Eilertsen G?.Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.Lupus Sci Med.2016;3(1):e000162.
[24]Lawler J.The functions of thrombospondin-1 and-2.Curr Opin Cell Biol.2000;12(5):634-640.
[25]Krishna SM,Golledge J.The role of thrombospondin-1 in cardiovascular health and pathology.Int J Cardiol.2013;168(2):692-706.
[26]Lin CY,Lin CY,Chang IW,et al.Low thrombospondin 2expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.Am J Transl Res.2015;7(11):2423-2432.
[27]杨建东.血小板激活因子[J].中华危重病急救医学,1996,8(8):502-505.
[28]吴勇杰,周尔凤.血小板激活因子与血小板的相互作用[J].中国药理学通报,1987,3(3):176-179.
[29]Hammond JW,Lu SM,Gelbard HA.Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC,Elevated Intracel ular Calcium,and Modulation of Synapsin 1 Dynamics and Phosphorylation.Front Cell Neurosci.2016;9:505.
[30]王文革,王俭勤.纤溶酶原激活物抑制物1和器官纤维化[J].医学综述,2010,16(9):1308-1310.
[31]Eddy AA.Serine proteases,inhibitors and receptors in renal fibrosis.Thromb Haemost.2009;101(4):656-664.
[32]赵晶,戚基萍,王德生.纤溶酶原激活物抑制物和脑血栓[J].黑龙江医学,2002,26(2):95-96.
[33]Tofler GH,Massaro J,O'Donnell CJ,et al.Plasminogen activator inhibitor and the risk of cardiovascular disease:The Framingham Heart Study.Thromb Res.2016;140:30-35.
[34]刘向辉,陈松娥,刘桂华.内皮素与心血管疾病的研究进展[J].天津体育学院学报,2005,20(2):49-52.
[35]潘雪峰,董华进,宫泽辉.内皮素与心血管功能研究的最新进展[J].国际药学研究杂志,2007,34(1):12-16.
[36]甘金莲,樊有赋,陈晔,等.内皮素的特性与生理病理作用[J].生物学教学,2009,34(4):2-4.
[37]陈欢.高剂量Ang II对血管内皮细胞ACE、ACE2表达的影响及其分子机制[D].广州:南方医科大学,2013.
[38]龚勇珍.血栓素A_2受体研究进展[J].临床与病理杂志,2004,24(1):28-31.